A phase 1 pilot trial suggests that a novel egg-shell derived peptide may reduce Alzheimer’s biomarkers and improve …
A phase 1 pilot trial suggests that a novel egg-shell derived peptide may reduce Alzheimer’s biomarkers and improve …
One company faces regulatory setback while another achieves a Phase III victory, highlighting both urgency and uncertainty in …
First 16-week data from the APEX Part A trial reveal APG777 could raise the bar for biologics in …
SUMMIT trial shows bezuclastinib reduces symptom burden and mast cell markers significantly in non-advanced systemic mastocytosis
In the VERIFY study rusfertide demonstrated both safety and efficacy in reducing phlebotomy dependence for patients with polycythemia …
Company Overview and Focus Biodexa Pharmaceuticals PLC, a clinical-stage biotechnology company dedicated to developing innovative treatments for diseases …
Continued program expansion strengthens potential to deliver an all-oral, pan-genotypic next-generation HCV therapy.
Analysts predict transformative biotherapies to lead future cancer treatment breakthroughs, with Oncolytics poised for key role.
Dual GLP-1 and GIP receptor agonist VK2735 moves into pivotal trials targeting robust weight loss and glycemic control …
Novel agent ENT-03 demonstrates promising metabolic improvements and safety in first-in-human study, setting stage for further development in …
Already a subscriber? Log in